Loading clinical trials...
Loading clinical trials...
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Conditions
Interventions
BYM338 10 mg/kg
Placebo
Locations
9
United States
Novartis Investigative Site
Anaheim, California, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Miami Lakes, Florida, United States
Novartis Investigative Site
Orlando, Florida, United States
Novartis Investigative Site
Baton Rouge, Louisiana, United States
Start Date
February 1, 2017
Primary Completion Date
March 21, 2019
Completion Date
May 8, 2019
Last Updated
January 5, 2021
NCT06513026
NCT07112339
NCT06329375
NCT06945406
NCT06959901
NCT06574035
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions